Transcription
2020 - 2021RUTGERS PHARMACEUTICALINDUSTRY FELLOWSHIP PROGRAMIn partnership with
TABLE OF CONTENTSA Message from Leadership . 3About Merck .4Leadership Team .9Merck Research Laboratories (MRL) FellowshipsClinical Safety & Risk Management. 11Late Stage Clinical Development . 12Global Regulatory Affairs. 14Regulatory Affairs Advertising and Promotion . 15Regulatory Affairs International. 16Translational Pharmacology . 17Global Medical Affairs—Oncology . 18Global Medical Information . 19Global Scientific Content . 20Global Field Medical Center of Excellence . 21US Medical Affairs . 22Human Health (HH) FellowshipUS Oncology Marketing. 23Alumni Spotlight . 24Rutgers Component . 272
A MESSAGE FROMLEADERSHIPOn behalf of Merck & Co., and the Ernest Mario School of Pharmacy at Rutgers University, thank you for expressing yourinterest in the Pharmaceutical Industry Fellowship Program. As you move forward in your career, I encourage you to considerthe fellowship opportunities at Merck.Led by former fellows and senior members of the management team, Merck Research Laboratories (MRL) has designed twoyear fellowship programs that will offer you a tremendous opportunity to learn, grow, and be part of a dynamic and excitingculture in the areas of Translational Medicine, Clinical Sciences and Study Management, Clinical Safety & Risk Management,Global Regulatory Affairs, Global Medical Affairs, and Global Medical Information. In addition, Merck has expanded itsfellowship program into its Health Human (HH) division and offers a US Oncology Marketing fellowship. We believe thesecritical areas in the drug development process and commercial organization offer fellows a unique opportunity to build skillsand gain hands on experience that will be invaluable as they pursue a rewarding career in the pharmaceutical industry.We have a strong commitment to continually develop a program that can generate success for you, Rutgers University, andMerck. We recognize that you are among the best and the brightest coming out of pharmacy school, bringing a strong trackrecord of high achievement. Our program is designed to allow you to continue your success in a post-doctoral environmentand for us to work with and train the potential leaders of tomorrow.The fellowship program at Merck is occurring at an exciting time as we have the most powerful R&D engine in our company’shistory. Merck is a strong and diverse company with an extensive global reach. We have a broad pipeline, a number ofproducts to help people, and we are more passionate than ever about what matters most to our customers and the patientswe serve.At Merck, we see every employee as both a team member and a potential leader with the power to influence others throughhis or her actions. Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity, and teamwork of ouremployees. This fellowship program is a component of our organizational focus on people.As many of you will learn from the Merck fellowship leadership team during your interviews, we all take great pride in ourwork and our business of improving human health. We have an excellent program, and we’re looking for exceptionalcandidates to become a part of that program. I wish you the best of luck during the recruitment process and hope you willstrongly consider the unique fellowship opportunities at Merck.With Best Regards,Roy D. Baynes, M.D., Ph.D.Chief Medical Officer, Senior Vice PresidentGlobal Clinical DevelopmentMerck Research Laboratories3
ABOUTMERCKHISTORYCULTUREPHILANTHROPYPRODUCTS4
“We try to remember that medicine is for the patient. We try never to forget thatmedicine is for the people. It is not for the profits.The profits follow, and if we have remembered that, they have never failed to appear.The better we have remembered it, the larger they have been.”George W. Merck, Merck President and Chairman 1925-1957OUR RESPONSIBILITYWe are committed to bringing a spirit of invention to all that we do to help improve health and well-being around the world to expand access to health, operate ethically, protect the environmentand engage our employees. It is our responsibility to address the health needs of patients andsociety through transformational science: delivering vaccines and medicines that can help millionsaround the world.OUR VISIONTo make a difference in the lives of people globally through our innovative medicines and vaccines.We are committed to being the premier, research intensive biopharmaceutical company and arededicated to providing leading innovations and solutions for today and the future.OUR MISSIONTo discover, develop and provide innovative products and services that save and improve livesaround the world.OUR INSPIRATIONWe are inspired by a shared vision and a mission to save and improve lives.We work with purpose, driven by inventiveness and a passion for excellence. Every breakthroughwe create has the potential to build a healthier, more hopeful future for people everywhere.5
AT MERCK, WE ASPIRE TO SOLVE THE WORLD’SCHALLENGES TO HEALTH AND WELL-BEING TOENSURE THE CONTINUITY OF HUMAN PROGRESSWHAT WE DOHOW WE DO ITWHY IT TY201419421891Leaving Darmstadt,Germany, GeorgeMerck arrives in NewYork and establishesMerck & Co, Inc.Merck’s penicillin “G” isused in the first successful treatment of bloodinfection with penicillinin the U.S. Ramping upproduction for the warearns Merck the ArmyNavy “E” Award forexcellence in manufacturing.1971Measles, mumps, andrubella virus vaccine islaunched in an innovative combined form.1986Recombinant hepatitisB vaccine is launched –the first geneticallyengineered vaccineapproved for humans,and the first to preventcancer.2006The first vaccine toprevent cervical cancer(the second-leadingcause of cancer deathsamong women worldwide) is approved.2006The first DPP-4 inhibitorfor type 2 diabetes isapproved by the FDA.19441899The Merck Manualbegins publication,providing professionalswith the best availablemedical knowledge ofthe day.In collaboration withMerck, Dr. SelmanWaksman of RutgersUniversity producesstreptomycin, theworld’s first cure fortuberculosis. Merckwaives the patentrights.20091987Ivermectin is developedfor river blindness anddistributed free to allwho need it. As of 1987,the company has donated 2.5 million tablets(estimated value of 3.75 billion).Helping people fightcancer is our passion.The first anti-PD-1 forthe treatment of advanced melanomareceives approval foruse in the U.S.The company andSchering-Plough mergeto create a stronger,more diverse globalhealthcare company.2015The Nobel Prize in Medicine is awarded to Dr.William Campbell, oneof the scientists whodiscovered avermectin,which later led to thecreation of ivermectin,the key component ofthe company’s revolutionary anti-river blindness drug.201119531933The founder’s son,George W. Merck,launchesmajor new researchlaboratories in Rahway,New Jersey, soon leading to breakthroughs invitamins, antibiotics,and anesthetics.The merger with Sharp& Dohme brings toMerck important newexpertise in biologicaland vaccine researchand global distribution.1996Following a decade ofintensive research,Merck’s protease inhibitor is approved fortreating HIV in just 45days, one of the fastestFDA reviews to date.The company launchesthe 10-year Merck forMothers initiative, aglobal effort to bringthe issue of maternalmortality to the forefront of global consciousness.6
OUR KEY INITIATIVESMERCK FOR MOTHERSOur 10-year, 500 million initiative applies our scientific and business expertise toreduce maternal deaths worldwide.6,059,147 women in target countries have improved access to quality care. 12,170providers/community health workers trained in target countries.OUR COMMITMENT TO END RIVERBLINDNESSMore than 25 years ago, we committed to donate our medicine, Ivermectin — asmuch as needed, for as long as needed — with the goal to help eliminate riverblindness in affected areas in Africa, Latin America and Yemen.5.8 million dollars of direct investment in the program with 176 million treatmentsapproved. River blindness is now eliminated in Colombia, Ecuador and Mexico.MSD-WELLCOME TRUSTHILLEMAN LABORATORIESThis first-of-its-kind, nonprofit, R&D joint venture is focused on creating newvaccines, and adapting existing vaccines for low-income countries.Launched in 2009 with focus on low-cost vaccines treating a number of diseases.MERCK FELLOWSHIP FOR GLOBAL HEALTHOur corporate pro bono program connects our employees withnonprofit organizations worldwide to help increase access tohealth services and to education in local communities.130 RTC fellows between 2012 and 2016 from 22 different countries worked with33 nonprofit organizations.7
CURRENTLYPROMOTED PRODUCTS8
MERCK PROGRAMLEADERSHIPEXECUTIVE SPONSORSEric Rubin, MDExecutive SponsorSenior Vice PresidentClinical Research OncologyEarly DevelopmentJill DeSimone, B.S. PharmExecutive SponsorSenior Vice PresidentUS Oncology CommercialOperationsEliav Barr, MDExecutive SponsorSenior Vice PresidentGlobal Medical AffairsDean Y. Li, MD, PhDExecutive SponsorSenior Vice PresidentDiscovery Sciences andTranslational MedicineLEADERSHIP TEAMSauzanne Khalilieh, PharmDGowri Murthy, PharmD, MBARipal Shah, PharmDFellowship DirectorProgram AlumnaDistinguished ScientistTranslational PharmacologyFellowship DirectorProgram AlumnaDirectorWorldwide Regulatory GroupAnne Flanigan-Minnick, PhDOlivia Vanscoy, PharmDMedical Affairs Fellowship LeadExecutive DirectorGlobal Medical InformationGlobal Medical AffairsProfessional Development LeadProgram AlumnaDirectorGlobal Oncology Market AccessWyatt Chafin, PharmDChief FellowGlobal Medical Affairs - OncologyABOUTLEADERSHIPMERCKTEAMFELLOWSHIPSChief FellowLate Stage ClinicalDevelopment - OncologyALUMNIRUTGERSSPOTLIGHTCOMPONENT9
MERCK FELLOWSHIPS Clinical Safety & Risk Management Global Medical Affairs—Oncology Late Stage Clinical Development Global Medical Information Global Regulatory Affairs Global Scientific Content Regulatory Affairs Advertising andPromotion* Global Field Medical Center of Excellence U.S. Medical Affairs* U.S. Oncology Marketing (NEW) Regulatory Affairs International Translational Pharmacology*Not recruiting for 2020-202110
CLINICAL SAFETY & RISKMANAGEMENTWithin Global Regulatory Affairs and Clinical Safety (GRACS), the Clinical Safety & RiskManagement (CSRM) department’s mission is to improve public health by assuring thesafe use of Merck products worldwide through proactive safety assessment, effectiverisk management, and transparent risk communication throughout the developmentaland marketed product life-cycle.The goal of the CSRM fellowship is to prepare the fellow for a career in pharmacovigilanceand risk management in the pharmaceutical industry. This will be done through arigorous, hands-on training program that exposes the fellow to the various aspects ofglobal product safety in an industry setting.Under the general direction and mentoring of a CSRM Director, the fellow will developSuzanne Skarzynski, PharmDDirectorClinical Safety & Risk ManagementPRECEPTORexpertise in, and gradually assume greater responsibility for, the overall clinical riskmanagement and safety surveillance of assigned marketed products. The fellow will learnabout all aspects of safety surveillance, including assessing safety information, safetysignaling, along with ensuring completeness of that safety information in worldwidepackage circulars. The fellow will have joint responsibility for the development of periodicsafety update reports and risk management plans and will partner with appropriateMerck departments and therapeutic areas to ensure efforts are aligned to meet ourglobal risk management strategies for assigned products. The fellowship will also involveworking with the CSRM group to help develop processes for the improved functioning ofthe fellowship program, and implement specific initiatives to achieve identified goals.The fellow will have the opportunity to interact with other departments within Merck,Samuel Kwarteng, PharmDSecond Year Fellowsuch as Medical Affairs, Epidemiology, Clinical Research, Biostatistics, and RegulatoryAffairs to learn how Clinical Safety & Risk Management is incorporated throughout theorganization. Additionally, the fellow will learn how pharmaceutical manufacturers usedata to support research, development, approval, and access for new therapeuticproducts.Adam Saluccio, PharmDFirst Year FellowRecruiting: 1 GERSSPOTLIGHTCOMPONENT11
LATE STAGE CLINICALDEVELOPMENTGlobal Clinical Trial Operations (GCTO) supports Merck’sMission to discover, develop, and provide innovative productsand services that save and improve lives around the world.Clinical Sciences & Study Management (CSSM) is asubfunctionalunitwithinGCTOacc
Merck & o, Inc. 1899 The Merck Manual begins publication, providing professionals with the best available medical knowledge of the day. (estimated value of 1933 The merger with Sharp The founder’s son, George W. Merck, launches Following a decade of major new research laboratories in Rahway, New Jersey, soon lead-ing to breakthroughs in vitamins, antibiotics, and anesthetics. FDA reviews to .
